Aspirin and other COX-1 inhibitors

Handbook of Experimental Pharmacology

Volumn 210, Issue , 2012, Pages 137-164

  Patrono, Carlo ^a   Rocca, Bianca ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Aspirin; Atherothrombosis; Cyclooxygenase inhibitors; Gastrointestinal bleeding; Interindividual variability

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; DICLOFENAC; ESOMEPRAZOLE; FLURBIPROFEN; HEPARIN; IBUPROFEN; INDOBUFEN; LOW MOLECULAR WEIGHT HEPARIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE; SULFINPYRAZONE; THROMBOXANE A2; TICLOPIDINE; TRIFLUSAL; WARFARIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOWN REGULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ESSENTIAL HYPERTENSION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GRAFT OCCLUSION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LOW BIRTH WEIGHT; LOW DRUG DOSE; MATERNAL HYPERTENSION; NONHUMAN; PATIENT COMPLIANCE; PEPTIC ULCER BLEEDING; PLACENTA INSUFFICIENCY; POLYCYTHEMIA VERA; PREECLAMPSIA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; STABLE ANGINA PECTORIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM; ANIMAL; ATHEROSCLEROSIS; FEMALE; PHYSIOLOGY; PREGNANCY; REVIEW; VEIN THROMBOSIS;

ANIMALS; ASPIRIN; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; PLACENTAL INSUFFICIENCY; PREGNANCY; VENOUS THROMBOSIS;

EID: 84867175707     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-29423-5_6     Document Type: Article

References (90)

1. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P (2008) Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:630S-669S
2. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomized trials of antiplatelet therapy: III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 308:235-243
3. Antithrombotic Trialists Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 324:71-86
4. Antithrombotic Trialists' (ATT) Collaboration (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849-1860
5. Anzellotti P, Capone ML, Jeyam A, Tacconelli S, Bruno A, Tontodonati P, Di Francesco L, Grossi L, Renda G, Merciaro G, Di Gregorio P, Price TS, Garcia Rodriguez LA, Patrignani P (2011) Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum 63:850-859
6. Bala M, Chin CN, Logan AT, Amin T, Marnett LJ, Boutaud O, Oates JA (2008) Acetylation of prostaglandin H2 synthases by aspirin is regulated by the redox state of the enzymes. Biochem Pharmacol 75:1472-1481
7. Baroletti S, Dell'Orfano H (2010) Medication adherence in cardiovascular disease. Circulation 121:1455-1458
8. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J (2008) Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:844S-866S
9. Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, Guyatt GH, Mark DB, Harrington RA, American College of Chest Physicians (2008) The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:776S-814S
10. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O'Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337:1030-1036
11. Born GVR, Patrono C (2006) Antiplatelets drugs. Br J Pharmacol 147:S241-S251
12. Brochier ML (1993) Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. Eur Heart J 14:951-957
13. Burch JW, Stanford PW, Majerus PW (1979) Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 61:314-319
14. Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P (2004) Clinical pharmacology of platelet, monocyte and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109:1468-1471
15. Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, Di Gregorio P, Merciaro G, Patrignani P (2005) Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45:1295-1301
16. CAST (Chinese Acute Stroke Trial) Collaborative Group (1997) CAST: randomised placebocontrolled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet 349:1641-1649
17. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809-1817
18. Cattaneo M (2010) New P2Y12 inhibitors. Circulation 121:171-179
19. Chan FK, Chung SCS, Suen BY, Lee YT, Leung WK, Leung VK, Wu JC, Lau JY, Hui Y, Lai MS, Chan HL, Sung JJ (2001) Preventing recurrent upper gastrointestinal bleeding in patients with elicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344:967-973
20. Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ (2005) Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352:238-244
21. Clarke RJ, Mayo G, Price P, FitzGerald GA (1991) Suppression of thromboxane A2 but not systemic prostacyclin by controlled-release aspirin. N Engl J Med 325:1137-1141
22. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ (2006) Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 37:2153-2158
23. Cruz-Fernandez JM, Lopez-Bescos L, García-Dorado D, López García-Aranda V, Cabadés A, Martín-Jadraque L, Velasco JA, Castro-Beiras A, Torres F, Marfil F, Navarro E (2000) Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J 21:457-465
24. Current-Oasis 7 Investigators (2010) Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 363:930-942
25. Davi G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357:2482-2494
26. De Abajo FJ, García Rodríguez LA (2001) Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 1:1
27. Demers LM, Budin R, Shaikh B (1980) The effects of aspirin on megakaryocyte prostaglandin production. Proc Soc Exp Biol Med 163:24-29
28. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996) European Stroke Prevention Study: II. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143:1-13
29. Dragani A, Pascale S, Recchiuti A, Mattoscio D, Lattanzio S, Petrucci G, Mucci L, Ferrante E, Habib A, Ranelletti FO, Ciabattoni G, Davi G, Patrono C, Rocca B (2010) The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-insensitive essential thrombocythemia: implications for antiplatelet therapy. Blood 115:1054-1061
30. Duley L, Henderson-Smart D, Knight M, King J (2001) Antiplatelet drugs for prevention of preeclampsia and its consequences: systematic review. BMJ 322:329-333
31. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2002) Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650-1655
32. Eikelboom JW, Hankey GJ, ThomJ, Bhatt DL, Steg PG, Montalescot G, Johnston SC, Steinhubl SR, Mak KH, Easton JD, HammC, Hu T, Fox KA, Topol EJ, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators (2008) Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 118:1705-1712
33. Farrel B, Godwin J, Richards S, Warlow C (1991) The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54:1044-1054
34. FitzGerald GA, Patrono C (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345:433-442
35. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ 2nd, Lawson JA, Brash AR (1983) Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71:676-688
36. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD, Aspirin for Asymptomatic Atherosclerosis Trialists (2010) Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303:841-848
37. Frelinger AL III, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD (2009) Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 120:2586-2596
38. García Rodríguez LA, Hernández-Díaz S, de Abajo FJ (2001) Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 52:563-571
39. García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S (2011) Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 123:1108-1115
40. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest 133:381S-453S
41. Grosser T, Fries S, FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116:4-15
42. Grosser T, Smyth E, FitzGerald GA (2010) Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout. In: Goodman & Gilman's the pharmacological basis of therapeutics, 12th edn. McGraw Hill, New York
43. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762
44. International Stroke Trial Collaborative Group (1997) The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet 349:1569-1581
45. ISIS-2 Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349-360
46. Iso H, Hennekens CH, Stampfer MJ, Rexrode KM, Colditz GA, Speizer FE, Willett WC, Manson JE (1999) Prospective study of aspirin use and risk of stroke in women. Stroke 30:1764-1771
47. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C (2006) Do selective cyclooxygenase- 2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332:1302-1308
48. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S (1996) Risk of aspirinassociated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348:1413-1416
49. Krasopoulos G, Brister SJ, Beattie WS, Elliot RF, Buchanan MR (2008) Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336:195-198
50. Lai KC, Chu KM, Hui WM, Wong BC, Hung WK, Loo CK, Hu WH, Chan AO, Kwok KF, Fung TT, Wong J, Lam SK (2006) Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 4:860-865
51. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T, for the European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114-124
52. Latini R, Tognoni G,Maggioni AP, Baigent C,Braunwald E, Chen ZM,Collins R, Flather M, Franzosi MG, Kjekshus J, Køber L, Liu LS, Peto R, Pfeffer M, Pizzetti F, Santoro E, Sleight P, Swedberg K, Tavazzi L, Wang W, Yusuf S (2000) Clinical effects of early ACE inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: meta-analysis of individual data from nearly 96,000 randomized patients. J Am Coll Cardiol 35:1801-1807
53. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS (2006) Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47:27-33
54. Loll PJ, Picot D, Garavito RM (1995) The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 2:637-643
55. Matías-Guiu J, Ferro JM, Alvarez-Sabín J, Torres F, Jiménez MD, Lago A, Melo T (2003) Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction. The TACIP Study: a randomized, double-blind, multicenter trial. Stroke 34:840-848
56. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96:272-277
57. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A, Oh-ishi S, Narumiya S (1997) Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388:678-682
58. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y, for the JPAD Trial Investigators (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. A randomized controlled trial. JAMA 300:2134-2141
59. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pocaterra D, Ragazzoni E, Rolandi G, Rocca B, Patrono C (2012) Thromboxane biosynthesis in aspirin-treated essential thrombocythemia is explained by abnormal megakaryopoiesis and accelerated renewal of the drug target: evidence from biochemical measurements and inhibitor trials. Blood 119:3595-3603
60. Patrignani P, Filabozzi P, Patrono C (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69:1366-1372
61. Patrono C (2003) Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 1:1710-1713
62. Patrono C, Rocca B (2010) The future of antiplatelet therapy in cardiovascular disease. Annu Rev Med 61:49-61
63. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davi G, Forni L (1985) Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72:1177-1184
64. Patrono C, García Rodríguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373-2383
65. Patrono C, Baigent C, Hirsh J, Roth G (2008) Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:199S-233S
66. Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet J-P, De Caterina R, Gulba D, Huber K, Husted S, Kristensen SD, Morais J, Neumann F-J, Rasmussen LH, Siegbahn A, Steg P-G, Storey RF, Van de Werf F, Verheugt F (2011) Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 32(23):2922-2932
67. Pedersen AK, FitzGerald GA (1984) Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclo-oxygenase. N Engl J Med 311:1206-1211
68. Pedersen AK, FitzGerald GA (1985) Cyclooxygenase inhibition, platelet function and drug metabolite formation during chronic administration of sulfinpyrazone in man. Clin Pharmacol Ther 37:36-42
69. Peters RJG, Mehta SR, Fox KAA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S (2003) Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes. Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108:1682-1687
70. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group (2000) Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 355:1295-1302
71. Ramis J, Torrent J, Mis R, Conte L, Barbanoj MJ, Jané J, Forn J (1990) Pharmacokinetics of triflusal after single and repeated doses in man. Int J Clin Pharmacol Ther Toxicol 28:344-349
72. Reilly IAG, FitzGerald GA (1987) Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69:180-186
73. Renda G, Tacconelli S, Capone ML, Sacchetta D, Santarelli F, Sciulli MG, Zimarino M, Grana M, D'Amelio E, Zurro M, Price TS, Patrono C, De Caterina R, Patrignani P (2006) Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 80:264-274
74. Rocca B, Patrono C (2005) Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 8:1597-1602
75. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, Melloni E, Maggiano N, Zauli G, Patrono C (2002) Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 99:7634-7639
76. Roth GJ, Majerus PW (1975) The mechanism of the effect of aspirin on human platelets: I. Acetylation of a particulate fraction protein. J Clin Invest 56:624-632
77. Roth GJ, Stanford N, Majerus PW (1975) Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 72:3073-3077
78. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW (2010) Longterm effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741-1750
79. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patients data from randomised trials. Lancet 377:31-41
80. Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, Davi G, Patrono C (2009) Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays. J Am Coll Cardiol 53:667-677
81. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A (2005) Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 95:973-975
82. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ (2008) Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest 133:546S-592S
83. Smith WL, Garavito RM, DeWitt DL (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271:33157-33160
84. Stroke Prevention in Atrial Fibrillation Study (1991) Final results. Circulation 84:527-539
85. Taylor DW, Barnett HJM, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, Simard D, Silver FL, Hachinski V, Clagett GP, Barnes R, Spence JD (1999) Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 353:2179-2184
86. Teo KK, Yusuf S, Pfeffer M, Torp-Pedersen C, Kober L, Hall A, Pogue J, Latini R, Collins R, ACE Inhibitors Collaborative Group (2002) Effects of long-term treatment with angiotensinconverting- enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 360:1037-1043
87. The Dutch TIA Trial Study Group (1991) A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 325:1261-1266
88. Topper JN, Cai J, Falb D, Gimbrone MA Jr (1996) Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 93:10417-10422
89. Van Kooten F, Ciabattoni G, Patrono C, Schmitz PIM, Van Gijn J, Koudstaal PJ (1994) Evidence for episodic platelet activation in acute ischemic stroke. Stroke 25:278-281
90. Zanchetti A, Hansson L, Leonetti G, Rahn KH, Ruilope L, Warnold I, Wedel H (2002) Low-dose aspirin does not interefere with the blood pressure-lowering effects of antihypertensive therapy. J Hypertens 20:1015-1022